Anzeige
Mehr »
Dienstag, 23.06.2026 - Börsentäglich über 12.000 News
Schuldenfrei, 1,5 Mio. Unzen Gold und Produktion ab 2027: Vor dem Ausbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVT8 | ISIN: CH1125843347 | Ticker-Symbol: 90B
Tradegate
22.06.26 | 17:47
4,760 Euro
+1,71 % +0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SOPHIA GENETICS SA Chart 1 Jahr
5-Tage-Chart
SOPHIA GENETICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
4,6804,82010:29
4,6804,82010:26

Aktuelle News zur SOPHIA GENETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoSOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting167Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of...
► Artikel lesen
MoSOPHiA GENETICS SA - 6-K, Report of foreign issuer3
FrSOPHiA GENETICS schließt öffentliches Angebot über 57,5 Millionen US-Dollar ab2
FrSOPHiA GENETICS closes $57.5M public offering1
FrSOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares302BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the...
► Artikel lesen
MiSOPHiA GENETICS prices $50M public offering at $4.75 per share5
MiSOPHiA GENETICS prices $50M public offering at $4.75/share1
SOPHIA GENETICS Aktie jetzt für 0€ handeln
16.06.SOPHiA GENETICS kündigt öffentliches Aktienangebot an2
16.06.Kapitalerhöhung angekündigt: Aktie von SOPHiA GENETICS gibt nach2
16.06.Stocks to watch on Tuesday after hours: LZB, AMCX, SOPH2
16.06.SOPHiA GENETICS announces public offering of ordinary shares1
16.06.SOPHiA GENETICS files for proposed underwritten public offering1
10.06.SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting372Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the BoardBOSTON and ROLLE, Switzerland...
► Artikel lesen
08.06.Sophia Genetics, Memorial Sloan Kettering sign strategic collab for AI-powered precision oncology hub1
04.06.SOPHiA GENETICS, MSK sign MOU for precision oncology venture2
04.06.SOPHiA GENETICS SA - 6-K, Report of foreign issuer1
04.06.SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center138SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology NEW YORK, June...
► Artikel lesen
19.05.SOPHiA GENETICS SA - 6-K, Report of foreign issuer2
13.05.Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.327LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading...
► Artikel lesen
06.05.BTIG reiterates Sophia Genetics stock rating on strong Q1 growth19
Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1